Skip to main content
SpringerLink
Log in

Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Reversible posterior leukoencephalopathy syndrome (RPLS), also known frequently as posterior reversible encephalopathy syndrome (PRES), is a characteristic acute neuro-radiology syndrome with clinical presentation that typically includes acute hypertension, seizures and other neurological symptoms and signs. Many patients with RPLS have (a history of) pre-existing hypertension and in receipt of diuretics. It is being diagnosed more frequently and in association with an increasing number of morbidities and medications. Drugs most frequently implicated are immunosuppressant drugs and anticancer agents, including a number of anti-angiogenic tyrosine kinase inhibitors (TKIs). Hypomagnesaemia is a frequent finding at presentation in RPLS patients, which is known to lead to or aggravate hypertension. Pre-eclampsia, a variant of RPLS, responds effectively to intravenous magnesium. Cyclosporin, tacrolimus and some TKIs that induce RPLS are also known to give rise to both hypertension and hypomagnesaemia. This raises an interesting hypothesis that hypomagnesaemia may play a contributory role in triggering RPLS in some patients by acutely raising the blood pressure further. Additional systematic studies are required to test this hypothesis. If the hypothesis is confirmed, hypomagnesaemia offers an effective target for risk mitigation and prevention of RPLS in patients identified at risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shah RR. Hyperglycaemia induced by novel anticancer agents: an undesirable complication or a potential therapeutic opportunity? Drug Saf. 2016. doi:10.1007/s40264-016-0485-y.

  2. European Medicines Agency. Approval of nintedanib (VARGATEF) for NSCLC (21 November 2014). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607.pdf. Accessed 21 July 2016.

  3. Shah RR. Tyrosine kinase inhibitors-induced interstitial lung disease: clinical features, diagnostic challenges and therapeutic dilemmas. Drug Saf. 2016;39:1073–91.

    Article  CAS  PubMed  Google Scholar 

  4. Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013;36:413–26.

    Article  CAS  PubMed  Google Scholar 

  5. Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11:172–91.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36:295–316.

    Article  CAS  PubMed  Google Scholar 

  7. Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 2015;38:693–710.

    Article  CAS  PubMed  Google Scholar 

  8. Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore). 2014;93:333–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhang ZF, Wang T, Liu LH, Guo HQ. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One. 2014;9:e90135.

    Article  PubMed  PubMed Central  Google Scholar 

  10. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95:1–46.

    Article  PubMed  CAS  Google Scholar 

  11. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500.

    Article  CAS  PubMed  Google Scholar 

  12. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036–42.

    Article  CAS  PubMed  Google Scholar 

  13. Chardain A, Mesnage V, Alamowitch S, Bourdain F, Crozier S, Lenglet T, et al. Posterior reversible encephalopathy syndrome (PRES) and hypomagnesemia: a frequent association? Rev Neurol (Paris). 2016;172:384–8.

    Article  CAS  PubMed  Google Scholar 

  14. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017. doi:10.1007/s00415-016-8377-8.

    PubMed  Google Scholar 

  15. Jung SM, Moon SJ, Kwok SK, Ju JH, Park KS, Park SH, et al. Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome. Lupus. 2013;22:885–91.

    Article  CAS  PubMed  Google Scholar 

  16. Shaharir SS, Remli R, Marwan AA, Said MS, Kong NC. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: pooled analysis of the literature reviews and report of six new cases. Lupus. 2013;22:492–6.

    Article  CAS  PubMed  Google Scholar 

  17. Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol. 2011;147:1197–202.

    Article  PubMed  Google Scholar 

  18. Liman TG, Bohner G, Heuschmann PU, Endres M, Siebert E. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol. 2012;259:155–64.

    Article  CAS  PubMed  Google Scholar 

  19. Song T, Rao Z, Tan Q, Qiu Y, Liu J, Huang Z, et al. Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review. Medicine (Baltimore). 2016;95:e3173.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep. 2008;10:86–91.

    Article  PubMed  Google Scholar 

  21. Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol. 2016;128:75–84.

    Article  PubMed  Google Scholar 

  22. Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J. 2009;39:826–34.

    Article  CAS  PubMed  Google Scholar 

  23. Rykken JB, McKinney AM. Posterior reversible encephalopathy syndrome. Semin Ultrasound CT MR. 2014;35:118–35.

    Article  PubMed  Google Scholar 

  24. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14:914–25.

    Article  PubMed  Google Scholar 

  25. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29:1043–9.

    Article  CAS  PubMed  Google Scholar 

  26. Lamy C, Oppenheim C, Mas JL. Posterior reversible encephalopathy syndrome. Handb Clin Neurol. 2014;121:1687–701.

    Article  CAS  PubMed  Google Scholar 

  27. Marra A, Vargas M, Striano P, Del Guercio L, Buonanno P, Servillo G. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses. 2014;82:619–22.

    Article  CAS  PubMed  Google Scholar 

  28. Bartynski WS, Boardman JF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2008;29:447–55.

    Article  CAS  PubMed  Google Scholar 

  29. Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J. 2001;77:24–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Legriel S, Pico F, Azoulay E. Chapter 56: understanding posterior reversible encephalopathy syndrome. In: Vincent JL, editor. Annual Update in Intensive Care and Emergency Medicine 2011. Berlin: Springer; 2011. p. 631–53.

    Chapter  Google Scholar 

  31. Granata G, Greco A, Iannella G, Granata M, Manno A, Savastano E, et al. Posterior reversible encephalopathy syndrome—insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2015;14:830–6.

    Article  CAS  PubMed  Google Scholar 

  32. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011;6:253–8.

    Article  PubMed  Google Scholar 

  34. Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist. 2015;20:806–11.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Datar S, Singh TD, Fugate JE, Mandrekar J, Rabinstein AA, Hocker S. Albuminocytologic dissociation in posterior reversible encephalopathy syndrome. Mayo Clin Proc. 2015;90:1366–71.

    Article  CAS  PubMed  Google Scholar 

  36. Chen TH, Lin WC, Kao WT, Tseng CM, Tseng YH. Posterior reversible encephalopathy syndrome with spinal cord involvement in children: clinicoradiologic findings and a retrospective comparison between adult and pediatric patients. J Child Neurol. 2017;32:112–9.

    Article  PubMed  Google Scholar 

  37. Moon SN, Jeon SJ, Choi SS, Song CJ, Chung GH, Yu IK, et al. Can clinical and MRI findings predict the prognosis of variant and classical type of posterior reversible encephalopathy syndrome (PRES)? Acta Radiol. 2013;54:1182–90.

    Article  PubMed  Google Scholar 

  38. Chhatrala H, Konda MK, Ghetiya S, Di Felice C, Aggarwal S, Stryker H. Association between posterior reversible encephalopathy syndrome and renal artery stenosis: a large retrospective analysis (abstract). J Gen Intern Med. 2016;31(Suppl):S217.

    Google Scholar 

  39. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. Am J Neuroradiol. 2007;28:1320–7.

    Article  CAS  PubMed  Google Scholar 

  40. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. Am J Roentgenol. 2007;189:904–12.

    Article  Google Scholar 

  41. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65:205–10.

    PubMed  Google Scholar 

  42. Burnett MM, Hess CP, Roberts JP, Bass NM, Douglas VC, Josephson SA. Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors. Clin Neurol Neurosurg. 2010;112:886–91.

    Article  PubMed  Google Scholar 

  43. Ni J, Zhou LX, Hao HL, Liu Q, Yao M, Li ML, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging. 2011;21:219–24.

    Article  PubMed  Google Scholar 

  44. Gupta V, Bhatia V, Khandelwal N, Singh P, Singhi P. Imaging findings in pediatric posterior reversible encephalopathy syndrome (PRES): 5 years of experience from a tertiary care center in India. J Child Neurol. 2016;31:1166–73.

    Article  PubMed  Google Scholar 

  45. Dandoy CE, Linscott LL, Davies SM, Leach JL, Myers KC, El-Bietar J, et al. Clinical utility of computed tomography and magnetic resonance imaging for diagnosis of posterior reversible encephalopathy syndrome after stem cell transplantation in children and adolescents. Biol Blood Marrow Transplant. 2015;21:2028–32.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Stevens CJ, Heran MK. The many faces of posterior reversible encephalopathy syndrome. Br J Radiol. 2012;85:1566–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Hugonnet E, Da Ines D, Boby H, Claise B, Petitcolin V, Lannareix V, et al. Posterior reversible encephalopathy syndrome (PRES): features on CT and MR imaging. Diagn Interv Imaging. 2013;94:45–52.

    Article  CAS  PubMed  Google Scholar 

  48. Neeb L, Hoekstra J, Endres M, Siegerink B, Siebert E, Liman TG. Spectrum of cerebral spinal fluid findings in patients with posterior reversible encephalopathy syndrome. J Neurol. 2016;263:30–4.

    Article  CAS  PubMed  Google Scholar 

  49. Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: long-term follow-up. J Neurol Neurosurg Psychiatry. 2010;81:773–7.

    Article  PubMed  Google Scholar 

  50. Legriel S, Schraub O, Azoulay E, Hantson P, Magalhaes E, Coquet I, For Critically Ill Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS), et al. Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One. 2012;7:e44534.

  51. Pande AR, Ando K, Ishikura R, Nagami Y, Takada Y, Wada A, et al. Clinicoradiological factors influencing the reversibility of posterior reversible encephalopathy syndrome: a multicenter study. Radiat Med. 2006;24:659–68.

    Article  PubMed  Google Scholar 

  52. Sha Z, Moran BP, McKinney AM 4th, Henry TR. Seizure outcomes of posterior reversible encephalopathy syndrome and correlations with electroencephalographic changes. Epilepsy Behav. 2015;48:70–4.

    Article  PubMed  Google Scholar 

  53. Heo K, Cho KH, Lee MK, Chung SJ, Cho YJ, Lee BI. Development of epilepsy after posterior reversible encephalopathy syndrome. Seizure. 2016;34:90–4.

    Article  PubMed  Google Scholar 

  54. Siebert E, Bohner G, Liebig T, Endres M, Liman TG. Factors associated with fatal outcome in posterior reversible encephalopathy syndrome: a retrospective analysis of the Berlin PRES study. J Neurol. 2016. doi:10.1007/s00415-016-8328-4.

  55. Onder AM, Lopez R, Teomete U, Francoeur D, Bhatia R, Knowbi O, et al. Posterior reversible encephalopathy syndrome in the pediatric renal population. Pediatr Nephrol. 2007;22:1921–9.

    Article  PubMed  Google Scholar 

  56. Ergün T, Lakadamyali H, Yilmaz A. Recurrent posterior reversible encephalopathy syndrome in a hypertensive patient with end-stage renal disease. Diagn Interv Radiol. 2008;14:182–5.

    PubMed  Google Scholar 

  57. Daniel NJ, Hernandez CL, Walker RA. Recurrent posterior reversible encephalopathy syndrome in a pediatric patient with end-stage renal disease. J Emerg Med. 2014;46:e39–42.

    Article  PubMed  Google Scholar 

  58. Hagemann G, Ugur T, Witte OW, Fitzek C. Recurrent posterior reversible encephalopathy syndrome (PRES). J Hum Hypertens. 2004;18:287–9.

    Article  CAS  PubMed  Google Scholar 

  59. Yamada A, Atsumi M, Tashiro A, Hiraiwa T, Ueda N. Recurrent posterior reversible encephalopathy syndrome in nephrotic syndrome: case report and review of the literature. Clin Nephrol. 2012;78:406–11.

    Article  PubMed  Google Scholar 

  60. Chang OH, Stanculescu A, Dola C, Rothwell WB. Recurrent posterior reversible encephalopathy syndrome potentially related to AIDS and end-stage renal disease: a case report and review of the literature. Case Rep Med. 2012;2012:914035.

    PubMed  PubMed Central  Google Scholar 

  61. Sweany JM, Bartynski WS, Boardman JF. “Recurrent” posterior reversible encephalopathy syndrome: report of 3 cases - PRES can strike twice! J Comput Assist Tomogr. 2007;31:148–56.

    Article  PubMed  Google Scholar 

  62. Food and Drug Administration. “Drugs at FDA”. Available at: http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 17 Jan 2017.

  63. Khurana A, Dasanu CA. Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects! J Oncol Pharm Pract. 2015;21:443–50.

    Article  CAS  PubMed  Google Scholar 

  64. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006;24:e48.

    Article  PubMed  Google Scholar 

  65. Dogan E, Aksoy S, Arslan C, Dede DS, Altundag K. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol. 2010;27:1436–7.

    Article  PubMed  Google Scholar 

  66. Laruelle M, Filleul B, Duprez T, Machiels JP. Posterior reversible encephalopathy syndrome associated with sorafenib and successful retreatment. Urol Int. 2016. doi:10.1159/000443970.

    Google Scholar 

  67. Tavil B, Isgandarova F, Bayhan T, Unal S, Kuskonmaz B, Gumruk F, et al. Sorafenib-induced posterior reversible encephalopathy syndrome in a child with FLT3-ITD-positive acute myeloid leukemia. J Pediatr Hematol Oncol. 2016;38:240–2.

    Article  CAS  PubMed  Google Scholar 

  68. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007;18:1745–7.

    Article  CAS  PubMed  Google Scholar 

  69. Martín G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007;25:3559.

    Article  PubMed  Google Scholar 

  70. Medioni J, Cojocarasu O, Banu E, Cassar-Queudeville A, Halimi P, Oudard S. Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Target Oncol. 2007;2:193–5.

    Article  Google Scholar 

  71. Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris). 2008;164:605–7.

    Article  CAS  PubMed  Google Scholar 

  72. Chen A, Agarwal N. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J. 2009;39:341–2.

    Article  CAS  PubMed  Google Scholar 

  73. Padhy BM, Shanmugam SP, Gupta YK, Goyal A. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol. 2011;71:777–9.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Khan KH, Fenton A, Murtagh E, McAleer JJ, Clayton A. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori. 2012;98:139e–42e.

    PubMed  Google Scholar 

  75. Hadj JO, Braven RD, Tillier C, Schrijver HM, Verheul HM, van der Vliet HJ. Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. Oncol Lett. 2012;3:1293–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Duchnowska R, Miciuk B, Bodnar L, Waśniewski L, Szczylik C. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib. J Oncol Pharm Pract. 2013;19:186–9.

    Article  PubMed  CAS  Google Scholar 

  77. Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC. Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med. 2014;2014:952624.

    PubMed  PubMed Central  Google Scholar 

  78. Fukui S, Toyoshima Y, Inoue T, Kagebayashi Y, Samma S. Reversible posterior leukoencephalopathy syndrome developing after restart of sunitinib therapy for metastatic renal cell carcinoma. Case Rep Med. 2016;2016:6852951.

    PubMed  PubMed Central  Google Scholar 

  79. Cavalli M, Saraceno L, Bosco G, Meola G. Reversible posterior leukoencephalopathy syndrome (RPLS) associated to therapy with sunitinib: first Italian case report and review of the literature (poster P12034)). Eur J Neurol. 2016;23(Suppl. 2):264.

    Google Scholar 

  80. Chelis L, Souftas V, Amarantidis K, Xenidis N, Chamalidou E, Dimopoulos P, et al. Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC Cancer. 2012;12:489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Asaithambi G, Peters BR, Hurliman E, Moran BP, Khan AS, Taylor RA. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma. J Clin Pharm Ther. 2013;38:175–6.

    Article  CAS  PubMed  Google Scholar 

  82. Foerster R, Welzel T, Debus J, Gruellich C, Jaeger D, Potthoff K. Posterior reversible leukoencephalopathy syndrome associated with pazopanib. Case Rep Oncol. 2013;6:204–8.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Miaris N, Maltezou M, Papaxoinis G, Visvikis A, Samantas E. Posterior reversible encephalopathy syndrome with concurrent nephrotic syndrome in a patient treated with pazopanib for metastatic renal cell carcinoma: case report and review of the literature. Clin Genitourin Cancer. 2016. doi:10.1016/j.clgc.2016.08.005.

    PubMed  Google Scholar 

  84. Myint ZW, Sen JM, Watts NL, Druzgal TJ, Nathan BR, Ward MD, et al. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Clin Colorectal Cancer. 2014;13:127–30.

    Article  PubMed  Google Scholar 

  85. Kim CA, Price-Hiller J, Chu QS, Tankel K, Hennig R, Sawyer MB, et al. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer. Invest New Drugs. 2014;32:1036–45.

    Article  PubMed  Google Scholar 

  86. Levy A, Benmoussa L, Ammari S, Albiges L, Escudier B. Reversible posterior leukoencephalopathy syndrome induced by axitinib. Clin Genitourin Cancer. 2014;12:e33–4.

    Article  PubMed  Google Scholar 

  87. Klomjit S, Hosiriluck N, Laengvejkal P, Panikkath D, Nugent K. Reversible posterior leukoencephalopathy syndrome induced by axitinib [abstract 412]. J Investig Med. 2015;63:444.

    Google Scholar 

  88. Baosman K, Malakoff G, Sirelkhatim A, Januja AU. A rare case of axitinib-induced posterior reversible encephalopathy syndrome (PRES) (abstract). J Gen Intern Med. 2016;31(Suppl):S518–9.

    Google Scholar 

  89. Márquez Fernández E, Marmesat Rodas B, Quesada Sanz MP, Guerra Estévez D, Villanueva Jiménez P. Use of vandetanib in medullary thyroid cancer (abstract PT048). Int J Clin Pharm. 2016;38:587.

    Google Scholar 

  90. Sawas T, Nigam N, Chalhoub W, Satoskar R. Pazopanib-induced acute liver failure and posterior reversible encephalopathy syndrome (abstract 1286). Am J Gastroenterol. 2014;109:S379.

    Google Scholar 

  91. Boukari F, Dugourd PM, Chassang M, Mondot L, Passeron T, Lacour JP et al. Posterior reversible encephalopathy syndrome due to combination vemurafenib and cobimetinib for metastatic melanoma. Pigment Cell Melanoma Res. 2016. doi:10.1111/pcmr.12562.

    Google Scholar 

  92. van der Veldt AA, van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol. 2007;18:1747–50.

    Article  PubMed  Google Scholar 

  93. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, et al. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012;78:76–80.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res. 2011;17:363–71.

    Article  CAS  PubMed  Google Scholar 

  95. Benjamin RS, Schöffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2011;68:69–77.

    Article  CAS  PubMed  Google Scholar 

  96. Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, et al. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129:86–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014;135:38–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. European Medicines Agency. “Side effects reports” Available at: http://www.adrreports.eu/en/search_subst.html. Accessed 17 Jan 2017.

  99. How J, Blattner M, Fowler S, Wang-Gillam A, Schindler SE. Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature. Neurologist. 2016;21:112–7.

    Article  PubMed  Google Scholar 

  100. Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH. Role of magnesium in cardiovascular diseases. Cardiol Rev. 2014;22:182–92.

    Article  PubMed  Google Scholar 

  101. Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7:8199–226.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  102. Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984;2(8412):1116–20.

    Article  CAS  PubMed  Google Scholar 

  103. June CH, Thompson CB, Kennedy MS, Nims J, Thomas ED. Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. Transplantation. 1985;39:620–4.

    Article  CAS  PubMed  Google Scholar 

  104. June CH, Thompson CB, Kennedy MS, Loughran TP Jr, Deeg HJ. Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. Transplantation. 1986;41:47–51.

    Article  CAS  PubMed  Google Scholar 

  105. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2011;13:843–7.

    Article  CAS  Google Scholar 

  106. Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension. 2016;68:324–33.

    Article  CAS  PubMed  Google Scholar 

  107. Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr. 2012;66:411–8.

    Article  CAS  PubMed  Google Scholar 

  108. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015;10:1257–72.

    Article  CAS  PubMed  Google Scholar 

  109. Massy ZA, Drüeke TB. Magnesium and cardiovascular complications of chronic kidney disease. Nat Rev Nephrol. 2015;11:432–42.

    Article  CAS  PubMed  Google Scholar 

  110. Fitzgerald RT, Samant RS, Kumar M, Van Hemert R, Angtuaco EJ. Features of infratentorial-predominant posterior reversible encephalopathy syndrome. Acta Neurol Belg. 2015;115:629–34.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013;88:301–5.

    Article  CAS  PubMed  Google Scholar 

  112. Schmidt V, Prell T, Treschl A, Klink A, Hochhaus A, Sayer HG. Clinical management of posterior reversible encephalopathy syndrome after allogeneic hematopoietic stem cell transplantation: a case series and review of the literature. Acta Haematol. 2016;135:1–10.

    Article  CAS  PubMed  Google Scholar 

  113. Hinduja A, Habetz K, Raina SK, Fitzgerald RT, Sahaya K. Predictors of seizures in patients with posterior reversible encephalopathy syndrome. Epilepsy Behav. 2016;61:97–101.

    Article  PubMed  Google Scholar 

  114. Demir BC, Ozerkan K, Ozbek SE, Yıldırım Eryılmaz N, Ocakoglu G. Comparison of magnesium sulfate and mannitol in treatment of eclamptic women with posterior reversible encephalopathy syndrome. Arch Gynecol Obstet. 2012;286:287–93.

    Article  CAS  PubMed  Google Scholar 

  115. Te Riele MG, Verrips A. Severe hypomagnesaemia causing reversible cerebellopathy. Cerebellum. 2014;13:659–62.

  116. Boulos MI, Shoamanesh A, Aviv RI, Gladstone DJ, Swartz RH. Severe hypomagnesemia associated with reversible subacute ataxia and cerebellar hyperintensities on MRI. Neurologist. 2012;18:223–5.

    Article  PubMed  Google Scholar 

  117. Cruz RJ Jr, DiMartini A, Akhavanheidari M, Iacovoni N, Boardman JF, Donaldson J, et al. Posterior reversible encephalopathy syndrome in liver transplant patients: clinical presentation, risk factors and initial management. Am J Transplant. 2012;12:2228–36.

    Article  PubMed  Google Scholar 

  118. Al-Tweigeri T, Magliocco AM, DeCoteau JF. Cortical blindness as a manifestation of hypomagnesemia secondary to cisplatin therapy: case report and review of literature. Gynecol Oncol. 1999;72:120–2.

    Article  CAS  PubMed  Google Scholar 

  119. Fitzgerald RT, Wright SM, Samant RS, Kumar M, Ramakrishnaiah RH, Van Hemert R, et al. Elevation of serum lactate dehydrogenase at posterior reversible encephalopathy syndrome onset in chemotherapy-treated cancer patients. J Clin Neurosci. 2014;21:1575–8.

    Article  CAS  PubMed  Google Scholar 

  120. Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: is there a difference between pregnant and non-pregnant patients? Eur Neurol. 2009;62:142–8.

    Article  CAS  PubMed  Google Scholar 

  121. Marrone LC, Gadonski G, Diogo LP, Brunelli JP, Martins WA, Laguna Gde O, et al. Posterior reversible encephalopathy syndrome: differences between pregnant and non-pregnant patients. Neurol Int. 2014;6:5376.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Okusanya BO, Oladapo OT, Long Q, Lumbiganon P, Carroli G, Qureshi Z, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG. 2016;123:356–66.

    Article  CAS  PubMed  Google Scholar 

  123. Chibber R, Al-Hijji J, Amen A, Fouda M, Kaleemullah ZM, El-Saleh E, et al. Maternal and perinatal outcome of eclampsia over a decade at a tertiary hospital in Kuwait. J Matern Fetal Neonatal Med. 2016;29:3132–7.

    PubMed  Google Scholar 

  124. Danmusa S, Coeytaux F, Potts J, Wells E. Scale-up of magnesium sulfate for treatment of pre-eclampsia and eclampsia in Nigeria. Int J Gynaecol Obstet. 2016;134:233–6.

    Article  PubMed  Google Scholar 

  125. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol. 1998;92:883–9.

  126. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 2004;190:1520–6.

    Article  CAS  PubMed  Google Scholar 

  127. Fong J, Gurewitsch ED, Volpe L, Wagner WE, Gomillion MC, August P. Baseline serum and cerebrospinal fluid magnesium levels in normal pregnancy and preeclampsia. Obstet Gynecol. 1995;85:444–8.

    Article  CAS  PubMed  Google Scholar 

  128. Apostol A, Apostol R, Ali E, Choi A, Ehsuni N, Hu B, et al. Cerebral spinal fluid and serum ionized magnesium and calcium levels in preeclamptic women during administration of magnesium sulfate. Fertil Steril. 2010;94:276–82.

    Article  CAS  PubMed  Google Scholar 

  129. Sun L, Kosugi Y, Kawakami E, Piao YS, Hashimoto T, Oyanagi K. Magnesium concentration in the cerebrospinal fluid of mice and its response to changes in serum magnesium concentration. Magnes Res. 2009;22:266–72.

    CAS  PubMed  Google Scholar 

  130. Food and Drug Administration. Drug label for cabozantinib (COMETRIQ) dated 20 May 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203756s002lbl.pdf. Accessed 17 Jan 2017.

  131. Food and Drug Administration. Drug label for lenvatinib (LENVIMA) dated 13 May 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206947s003lbl.pdf. Accessed 17 Jan 2017.

  132. Food and Drug Administration. Drug label for pazopanib (VOTRIENT) dated A5 August 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022465s023lbl.pdf. Accessed 17 Jan 2017.

  133. Food and Drug Administration. Drug label for sunitinib (SUTENT) dated 16 November 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021938s031lbl.pdf. Accessed 17 Jan 2017.

  134. Food and Drug Administration. Drug label for vandetanib (CAPRELSA) dated 26 July 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022405s010lbl.pdf. Accessed 17 Jan 2017.

  135. Costa A, Tejpar S, Prenen H, Van Cutsem E. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Target Oncol. 2011;6:227–33.

    Article  PubMed  Google Scholar 

  136. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8:387–94.

    Article  CAS  PubMed  Google Scholar 

  137. Izzedine H, Bahleda R, Khayat D, Massard C, Magné N, Spano JP, et al. Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol. 2010;73:213–9.

    Article  PubMed  Google Scholar 

  138. do Pazo-Oubiña F, Estefanell-Tejero A, Riu-Viladoms G, Anglada-Martínez H, Molas-Ferrer G, Creus-Baró N. Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy. J Clin Pharm Ther. 2013;38:101–3.

  139. Wang Q, Qi Y, Zhang D, Gong C, Yao A, Xiao Y, et al. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol. 2015;36:3471–82.

    Article  CAS  PubMed  Google Scholar 

  140. Fujii H, Iihara H, Suzuki A, Kobayashi R, Matsuhashi N, Takahashi T, et al. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2016;77:1209–15.

    Article  CAS  PubMed  Google Scholar 

  141. Palma JA, Gomez-Ibañez A, Martin B, Urrestarazu E, Gil-Bazo I, Pastor MA. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab. Neurologist. 2011;17:273–5.

    Article  PubMed  Google Scholar 

  142. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980–1.

    Article  CAS  PubMed  Google Scholar 

  143. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:981–2.

    CAS  Google Scholar 

  144. Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM. 2012;105:69–75.

    Article  CAS  PubMed  Google Scholar 

  145. Cross SN, Ratner E, Rutherford TJ, Schwartz PE, Norwitz ER. Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Rev Obstet Gynecol. 2012;5:2–8.

    PubMed  PubMed Central  Google Scholar 

  146. Wang W, Zhao LR, Lin XQ, Feng F. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer. World J Gastroenterol. 2014;20:6691–7.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Eryılmaz MK, Mutlu H, Salim DK, Musri FY, Coşkun HS. Fatal posterior reversible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. J Oncol Pharm Pract. 2016;22:806–10.

    Article  PubMed  Google Scholar 

  148. Food and Drug Administration. Drug label for bevacizumab (AVASTIN) dated 6 December 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125085s317lbl.pdf. Accessed 17 Jan 2017.

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Consultant, 8 Birchdale, Gerrards Cross, Buckinghamshire, UK

    Rashmi R. Shah

Authors
  1. Rashmi R. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rashmi R. Shah.

Ethics declarations

This is a review of data in the public domain and Dr. Shah declares compliance with all ethical standards.

Funding

No sources of funding were used to assist in the preparation of this review.

Conflict of interest

Dr. Rashmi Shah has no conflicts of interest that are relevant to the content of this review and did not receive any financial support for writing it. He was formerly a Senior Clinical Assessor at the Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK. He now provides expert consultancy services concerning the development and safety of drugs to a number of pharmaceutical companies.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shah, R.R. Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?. Drug Saf 40, 373–386 (2017). https://doi.org/10.1007/s40264-017-0508-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-017-0508-3

Keywords

Search

Navigation